$PCRX
Pacira BioSciences, Inc. Stock $pcrx

$pcrx Overview Financials Valuation SEC Filings Company Website

2015 Q1 Form 10-Q Financial Statement

#000139681415000006 Filed on April 30, 2015

Income Statement

Concept	2015 Q1	2014 Q1
Revenue	$58.32M	$36.66M
YoY Change	59.06%	216.41%
Cost Of Revenue	$17.58M	$18.13M
YoY Change	-3.02%	59.13%
Gross Profit	$40.74M	$18.54M
YoY Change	119.78%	9356.63%
Gross Profit Margin	69.85%	50.56%
Selling, General & Admin	$31.43M	$22.59M
YoY Change	39.13%	74.62%
% of Gross Profit	77.15%	121.87%
Research & Development	$5.967M	$5.204M
YoY Change	14.66%	-11.87%
% of Gross Profit	14.65%	28.08%
Depreciation & Amortization	$2.743M	$2.603M
YoY Change	5.38%	81.9%
% of Gross Profit	6.73%	14.04%
Operating Expenses	$54.98M	$45.92M
YoY Change	19.72%	51.89%
Operating Profit	$3.341M	-$9.258M
YoY Change	-136.09%	-50.35%
Interest Expense	$1.996M	$2.107M
YoY Change	-5.27%	38.71%
% of Operating Profit	59.74%
Other Income/Expense, Net	-$2.029M	-$2.219M
YoY Change	-8.56%	-55.04%
Pretax Income	$1.312M	-$11.48M
YoY Change	-111.43%	-51.33%
Income Tax	$52.00K	$0.00
% Of Pretax Income	3.96%
Net Earnings	$1.260M	-$11.48M
YoY Change	-110.98%	-50.4%
Net Earnings / Revenue	2.16%	-31.3%
Basic Earnings Per Share		-$0.34
Diluted Earnings Per Share	$31.10K	-$0.34
COMMON SHARES
Basic Shares Outstanding	36.24M shares	33.71M shares
Diluted Shares Outstanding	41.78M shares	33.71M shares

Balance Sheet

Concept	2015 Q1	2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$154.9M	$64.60M
YoY Change	139.78%	-41.38%
Cash & Equivalents	$40.90M	$18.76M
Short-Term Investments	$114.0M	$45.80M
Other Short-Term Assets	$4.100M	$2.600M
YoY Change	57.69%	-3.7%
Inventory	$36.26M	$15.36M
Prepaid Expenses
Receivables	$24.51M	$15.97M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$219.8M	$98.48M
YoY Change	123.15%	-23.65%
LONG-TERM ASSETS
Property, Plant & Equipment	$67.21M	$49.89M
YoY Change	34.71%	21.3%
Goodwill	$25.38M	$11.33M
YoY Change	124.08%	31.99%
Intangibles
YoY Change
Long-Term Investments	$19.90M
YoY Change
Other Assets	$2.432M	$3.353M
YoY Change	-27.47%	-12.8%
Total Long-Term Assets	$115.3M	$65.22M
YoY Change	76.77%	15.93%
TOTAL ASSETS
Total Short-Term Assets	$219.8M	$98.48M
Total Long-Term Assets	$115.3M	$65.22M
Total Assets	$335.0M	$163.7M
YoY Change	104.67%	-11.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.565M	$2.605M
YoY Change	113.63%	160.24%
Accrued Expenses	$25.30M	$16.91M
YoY Change	49.57%	71.32%
Deferred Revenue
YoY Change
Short-Term Debt	$104.1M	$100.0M
YoY Change	4.1%
Long-Term Debt Due	$0.00	$1.100M
YoY Change	-100.0%	22.22%
Total Short-Term Liabilities	$136.5M	$121.6M
YoY Change	12.23%	857.53%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$5.404M	$3.435M
YoY Change	57.32%	27.51%
Total Long-Term Liabilities	$5.404M	$3.435M
YoY Change	57.32%	-96.51%
TOTAL LIABILITIES
Total Short-Term Liabilities	$136.5M	$121.6M
Total Long-Term Liabilities	$5.404M	$3.435M
Total Liabilities	$151.0M	$128.0M
YoY Change	17.99%	10.86%
SHAREHOLDERS EQUITY
Retained Earnings	-$308.9M	-$307.9M
YoY Change	0.32%	20.44%
Common Stock	$36.00K	$34.00K
YoY Change	5.88%	3.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares	0.000 shares	0.000 shares
Shareholders Equity	$184.0M	$35.71M
YoY Change
Total Liabilities & Shareholders Equity	$335.0M	$163.7M
YoY Change	104.67%	-11.63%

Cashflow Statement

Concept	2015 Q1	2014 Q1
OPERATING ACTIVITIES
Net Income	$1.260M	-$11.48M
YoY Change	-110.98%	-50.4%
Depreciation, Depletion And Amortization	$2.743M	$2.603M
YoY Change	5.38%	81.9%
Cash From Operating Activities	-$870.0K	-$4.740M
YoY Change	-81.65%	-65.63%
INVESTING ACTIVITIES
Capital Expenditures	$7.874M	$3.808M
YoY Change	106.78%	29.88%
Acquisitions
YoY Change
Other Investing Activities	$8.070M	$12.83M
YoY Change	-37.1%	-124.06%
Cash From Investing Activities	$200.0K	$9.020M
YoY Change	-97.78%	-116.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$4.047M	$1.964M
YoY Change	106.06%	-97.72%
NET CHANGE
Cash From Operating Activities	-870.0K	-4.740M
Cash From Investing Activities	200.0K	9.020M
Cash From Financing Activities	$4.047M	$1.964M
Net Change In Cash	$4.047M	$1.964M
YoY Change	106.06%	-87.84%
FREE CASH FLOW
Cash From Operating Activities	-$870.0K	-$4.740M
Capital Expenditures	$7.874M	$3.808M
Free Cash Flow	-$8.744M	-$8.548M
YoY Change	2.29%	-48.88%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q1	dei	Amendment Flag AmendmentFlag	false
CY2015Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2015Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015Q1	dei	Document Period End Date DocumentPeriodEndDate	2015-03-31
CY2015Q1	dei	Document Type DocumentType	10-Q
CY2015Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001396814
CY2015Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	36443244	shares
CY2015Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2015Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2015Q1	dei	Entity Registrant Name EntityRegistrantName	Pacira Pharmaceuticals, Inc.
CY2014Q1	pcrx	Amortization Of Other Assets And Unfavorable Lease Obligation AmortizationOfOtherAssetsAndUnfavorableLeaseObligation	122000	USD
CY2015Q1	pcrx	Amortization Of Other Assets And Unfavorable Lease Obligation AmortizationOfOtherAssetsAndUnfavorableLeaseObligation	122000	USD
CY2014Q4	pcrx	Available For Sale Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	13000	USD
CY2015Q1	pcrx	Available For Sale Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	13000	USD
CY2014Q4	pcrx	Available For Sale Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	93000	USD
CY2015Q1	pcrx	Available For Sale Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	41000	USD
CY2014Q1	pcrx	Collaborative Licensing And Development Revenue CollaborativeLicensingAndDevelopmentRevenue	252000	USD
CY2015Q1	pcrx	Collaborative Licensing And Development Revenue CollaborativeLicensingAndDevelopmentRevenue	356000	USD
CY2014Q1	pcrx	Compensationexpensefromemployeestockpurchaseplan Compensationexpensefromemployeestockpurchaseplan	0	USD
CY2015Q1	pcrx	Compensationexpensefromemployeestockpurchaseplan Compensationexpensefromemployeestockpurchaseplan	211000	USD
CY2014Q1	pcrx	Compensationexpensefromstockoptionsemployees Compensationexpensefromstockoptionsemployees	2409000	USD
CY2015Q1	pcrx	Compensationexpensefromstockoptionsemployees Compensationexpensefromstockoptionsemployees	6309000	USD
CY2014Q1	pcrx	Compensationexpensefromstockoptionsnonemployeeawards Compensationexpensefromstockoptionsnonemployeeawards	1566000	USD
CY2015Q1	pcrx	Compensationexpensefromstockoptionsnonemployeeawards Compensationexpensefromstockoptionsnonemployeeawards	997000	USD
CY2012Q2	pcrx	Contingent Payment Obligation Established For Sale Of Product In Connection With Acquisition ContingentPaymentObligationEstablishedForSaleOfProductInConnectionWithAcquisition	2000000	USD
CY2015Q1	pcrx	Conversion Request Convertible Senior Notes ConversionRequestConvertibleSeniorNotes	1500000	USD
CY2015Q1	pcrx	Debt Instrument Convertible Conversion Premium Shares DebtInstrumentConvertibleConversionPremiumShares	3500000	shares
CY2015Q1	pcrx	Debt Instrument Convertible Conversion Value DebtInstrumentConvertibleConversionValue	309600000	USD
CY2015Q1	pcrx	Goodwill Recordedfor Earn Out Payments GoodwillRecordedforEarnOutPayments	1620000	USD
CY2015Q1	pcrx	Income Tax Provision IncomeTaxProvision	100000	USD
CY2014Q1	pcrx	Increase Decrease In Royalty Interest Obligation IncreaseDecreaseInRoyaltyInterestObligation	181000	USD
CY2015Q1	pcrx	Increase Decrease In Royalty Interest Obligation IncreaseDecreaseInRoyaltyInterestObligation	276000	USD
CY2014Q4	pcrx	Long Term Debt Including Royalty Interest Obligation LongTermDebtIncludingRoyaltyInterestObligation	103376000	USD
CY2015Q1	pcrx	Long Term Debt Including Royalty Interest Obligation LongTermDebtIncludingRoyaltyInterestObligation	104135000	USD
CY2014	pcrx	Number Of Major Customers NumberOfMajorCustomers	3	customer
CY2015Q1	pcrx	Number Of Major Customers NumberOfMajorCustomers	3	customer
CY2014Q1	pcrx	Payment Of Contingent Consideration PaymentOfContingentConsideration	999000	USD
CY2012Q2	pcrx	Payment Obligation Arising Due To First Commercial Sale Of Product In Connection With Acquisition PaymentObligationArisingDueToFirstCommercialSaleOfProductInConnectionWithAcquisition	10000000	USD
CY2015Q1	pcrx	Payment Of Contingent Consideration PaymentOfContingentConsideration	1620000	USD
CY2014Q4	pcrx	Royalty Interest Obligation RoyaltyInterestObligation	276000	USD
CY2015Q1	pcrx	Royalty Interest Obligation RoyaltyInterestObligation	0	USD
CY2014Q4	pcrx	Royalty Interest Obligation Current RoyaltyInterestObligationCurrent	276000	USD
CY2015Q1	pcrx	Royalty Interest Obligation Current RoyaltyInterestObligationCurrent	0	USD
CY2015Q1	pcrx	Settlement Period Convertible Debt Conversion Request SettlementPeriodConvertibleDebtConversionRequest	P40D
CY2015Q1	pcrx	Total Goodwill Recordedfor Earn Out Payments TotalGoodwillRecordedforEarnOutPayments	9400000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6758000	USD
CY2015Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	5565000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	22366000	USD
CY2015Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	24511000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	28311000	USD
CY2015Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	25296000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	20114000	USD
CY2015Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	22777000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-80000	USD
CY2015Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-28000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	481334000	USD
CY2015Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	492898000	USD
CY2015Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7517000	USD
CY2014Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3975000	USD
CY2015Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7517000	USD
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2015Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2014Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1035000	USD
CY2015Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1035000	USD
CY2014Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000	USD
CY2015Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	USD
CY2014Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6995000	shares
CY2015Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1323000	shares
CY2014Q4	us-gaap	Assets Assets	326072000	USD
CY2015Q1	us-gaap	Assets Assets	335030000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	214257000	USD
CY2015Q1	us-gaap	Assets Current AssetsCurrent	219750000	USD
CY2014Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	143649000	USD
CY2015Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	133955000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12515000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18762000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37520000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	40897000	USD
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2015Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36150620	shares
CY2015Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36343731	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36150620	shares
CY2015Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36343731	shares
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	36000	USD
CY2015Q1	us-gaap	Common Stock Value CommonStockValue	36000	USD
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11477000	USD
CY2015Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1312000	USD
CY2014Q4	us-gaap	Convertible Debt ConvertibleDebt	120000000	USD
CY2015Q1	us-gaap	Convertible Debt ConvertibleDebt	120000000	USD
CY2014Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	103100000	USD
CY2015Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	104135000	USD
CY2014Q1	us-gaap	Cost Of Revenue CostOfRevenue	18127000	USD
CY2015Q1	us-gaap	Cost Of Revenue CostOfRevenue	17580000	USD
CY2015Q1	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	3500000	shares
CY2015Q1	us-gaap	Debt Instrument Convertible Threshold Consecutive Trading Days DebtInstrumentConvertibleThresholdConsecutiveTradingDays	P30D
CY2015Q1	us-gaap	Debt Instrument Convertible Threshold Percentage Of Stock Price Trigger DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger	1.3
CY2015Q1	us-gaap	Debt Instrument Convertible Threshold Trading Days DebtInstrumentConvertibleThresholdTradingDays	20	D
CY2014Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	16900000	USD
CY2015Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	15865000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1426000	USD
CY2015Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1426000	USD
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	9508000	USD
CY2015Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	9152000	USD
CY2014Q1	us-gaap	Depreciation Depreciation	2100000	USD
CY2015Q1	us-gaap	Depreciation Depreciation	2700000	USD
CY2014Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2603000	USD
CY2015Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2743000	USD
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.03
CY2015Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2014Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	14597000	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	14677000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	15000000	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	15000000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	403000	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	323000	USD
CY2014Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-8000	USD
CY2015Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2014Q4	us-gaap	Goodwill Goodwill	23761000	USD
CY2015Q1	us-gaap	Goodwill Goodwill	25381000	USD
CY2012Q2	us-gaap	Goodwill Goodwill	8000000	USD
CY2014Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11477000	USD
CY2015Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1312000	USD
CY2014Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2015Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	52000	USD
CY2014Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2015Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	160	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1531000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-4316000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1379000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2145000	USD
CY2014Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-252000	USD
CY2015Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-356000	USD
CY2014Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-193000	USD
CY2015Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7001000	USD
CY2014Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	278000	USD
CY2015Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	29000	USD
CY2014Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-237000	USD
CY2015Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-372000	USD
CY2014Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-1633000	USD
CY2015Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-1509000	USD
CY2014Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2015Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	6000	shares
CY2014Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2015Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	3652000	shares
CY2014Q1	us-gaap	Incremental Common Shares Attributable To Equity Unit Purchase Agreements IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements	0	shares
CY2015Q1	us-gaap	Incremental Common Shares Attributable To Equity Unit Purchase Agreements IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements	1000	shares
CY2014Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2015Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1885000	shares
CY2015Q1	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	200000	USD
CY2014Q1	us-gaap	Interest Expense InterestExpense	2107000	USD
CY2015Q1	us-gaap	Interest Expense InterestExpense	1996000	USD
CY2014Q1	us-gaap	Interest Paid InterestPaid	2251000	USD
CY2015Q1	us-gaap	Interest Paid InterestPaid	2297000	USD
CY2014Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	11383000	USD
CY2015Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	13398000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	29263000	USD
CY2015Q1	us-gaap	Inventory Net InventoryNet	36264000	USD
CY2014Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	9263000	USD
CY2015Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	10355000	USD
CY2014Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	8617000	USD
CY2015Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	12511000	USD
CY2014Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	42000	USD
CY2015Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	155000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	154927000	USD
CY2015Q1	us-gaap	Liabilities Liabilities	151009000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	326072000	USD
CY2015Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	335030000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	140010000	USD
CY2015Q1	us-gaap	Liabilities Current LiabilitiesCurrent	136453000	USD
CY2014Q4	us-gaap	Long Term Debt LongTermDebt	103100000	USD
CY2015Q1	us-gaap	Long Term Debt LongTermDebt	104135000	USD
CY2015Q1	us-gaap	Long Term Investments LongTermInvestments	19938000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	6247000	USD
CY2014Q4	us-gaap	Long Term Investments LongTermInvestments	24431000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	3377000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1964000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4047000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	9019000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1163000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4736000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	493000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-11477000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	1260000	USD
CY2014Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2219000	USD
CY2015Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2029000	USD
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	45920000	USD
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	54975000	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9258000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	3341000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	46783000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	7876000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	7660000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	7459000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	7263000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	11787000	USD
CY2015Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	4738000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2588000	USD
CY2015Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2432000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0	USD
CY2015Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	52000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2015Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	52000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5409000	USD
CY2015Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5404000	USD
CY2014Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-34000	USD
CY2015Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-117000	USD
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3808000	USD
CY2015Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9237000	USD
CY2014Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	18946000	USD
CY2015Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	49937000	USD
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4461000	USD
CY2015Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4089000	USD
CY2014Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	32772000	USD
CY2015Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	59631000	USD
CY2014Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1964000	USD
CY2015Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4047000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	80746000	USD
CY2015Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	89983000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	60632000	USD
CY2015Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	67206000	USD
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5204000	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5967000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1509000	USD
CY2015Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	0	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-310145000	USD
CY2015Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-308885000	USD
CY2014Q1	us-gaap	Revenues Revenues	36662000	USD
CY2015Q1	us-gaap	Revenues Revenues	58316000	USD
CY2014Q1	us-gaap	Royalty Expense RoyaltyExpense	120000	USD
CY2015Q1	us-gaap	Royalty Expense RoyaltyExpense	71000	USD
CY2014Q1	us-gaap	Royalty Revenue RoyaltyRevenue	668000	USD
CY2015Q1	us-gaap	Royalty Revenue RoyaltyRevenue	874000	USD
CY2014Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	35742000	USD
CY2015Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	57086000	USD
CY2014Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	22589000	USD
CY2015Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	31428000	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3975000	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7517000	USD
CY2015Q1	us-gaap	Share Price SharePrice	88.85
CY2014Q4	us-gaap	Short Term Investments ShortTermInvestments	119138000	USD
CY2015Q1	us-gaap	Short Term Investments ShortTermInvestments	113989000	USD
CY2015Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4047000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	171145000	USD
CY2015Q1	us-gaap	Stockholders Equity StockholdersEquity	184021000	USD
CY2014Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	139000	USD
CY2015Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	31000	USD
CY2014Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	0	shares
CY2015Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	0	shares
CY2014Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33711000	shares
CY2015Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41779000	shares
CY2014Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33711000	shares
CY2015Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36235000	shares

Files In Submission

Name	View Source	Status
0001396814-15-000006-index-headers.html	Edgar Link	pending
0001396814-15-000006-index.html	Edgar Link	pending
0001396814-15-000006.txt	Edgar Link	pending
0001396814-15-000006-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
pcrx-20150331.xml	Edgar Link	completed
pcrx-20150331.xsd	Edgar Link	pending
pcrx-20150331_cal.xml	Edgar Link	unprocessable
pcrx-20150331_def.xml	Edgar Link	unprocessable
pcrx-20150331_lab.xml	Edgar Link	unprocessable
pcrx-20150331_pre.xml	Edgar Link	unprocessable
pcrx-33115xex101.htm	Edgar Link	pending
pcrx-33115xex102.htm	Edgar Link	pending
pcrx-33115xex103.htm	Edgar Link	pending
pcrx-33115xex104.htm	Edgar Link	pending
pcrx-33115xex105.htm	Edgar Link	pending
pcrx-33115xex311.htm	Edgar Link	pending
pcrx-33115xex312.htm	Edgar Link	pending
pcrx-33115xex321.htm	Edgar Link	pending
pcrx-33115xex322.htm	Edgar Link	pending
pcrx-3312015x10xq.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PCRX
Pacira BioSciences, Inc. Stock $pcrx

2015 Q1 Form 10-Q Financial Statement

#000139681415000006 Filed on April 30, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCRX Pacira BioSciences, Inc. Stock $pcrx

2015 Q1 Form 10-Q Financial Statement

#000139681415000006 Filed on April 30, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PCRX
Pacira BioSciences, Inc. Stock $pcrx